What the research says about long-term outcomes The weight management field has learned hard lessons over decades
Follow UK guidelines: Aim to stay within the recommended limit of 14 units per week, spread over at least three days with several alcohol-free days
Read the research article 8
STEP 1 showed 14.9% body weight reduction at 2.4 mg weekly SELECT trial : Cardiovascular outcomes study showing 20% MACE reduction in patients with obesity and established CVD without diabetes FLOW trial : Kidney outcomes data demonstrating renal protective effects Oral formulation : Rybelsus provides an oral dosing option at 7-14 mg daily Real-world data : Millions of prescriptions written, providing extensive post-marketing safety surveillance Survodutide Research# Survodutide's evidence base is growing but not yet mature: Phase 2 obesity trial : Demonstrated dose-dependent weight loss up to approximately 19% body weight reduction, exceeding typical GLP-1 monotherapy results Phase 2 MASH data : Histological improvement in liver biopsies, including reduction in hepatic steatosis and inflammation scores Phase 3 programs : Active Phase 3 trials for both obesity and MASH, with results anticipated to define the compound's clinical profile Mechanism validation : Clinical data support the dual mechanism concept, with evidence of both appetite reduction and increased energy expenditure Limitation : No regulatory approvals
Seventy day safety assessment of an orally ingested, L-glutamine-containing oat and yeast supplement for horses
There is also an issue of medication shortages: if you are unable to obtain semaglutide, it may be worthwhile discussing with your doctor alternative treatment options, including switching to a different weight loss medication
